12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

4-factor prothrombin complex concentrate regulatory update

FDA accepted for review a BLA from CSL for 4-factor prothrombin complex concentrate (PCC) to reverse vitamin K antagonist...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >